Arvinas, Inc. (ARVN) Insider Trading Activity
NASDAQ$6.07
Market Cap
$443.06M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
444 of 877
Rank in Industry
260 of 506
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
ARVN Insider Trading Activity
ARVN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $845,974 | 6 | 100 |
Related Transactions
| Loomis David K | Chief Accounting Officer | 0 | $0 | 2 | $26,731 | $-26,731 |
| Cacace Angela M | Chief Scientific Officer | 0 | $0 | 1 | $70,238 | $-70,238 |
| Berkowitz Noah | Chief Medical Officer | 0 | $0 | 1 | $74,372 | $-74,372 |
| Taylor Ian | President, R&D | 0 | $0 | 1 | $150,752 | $-150,752 |
| Houston John G | President and CEO | 0 | $0 | 1 | $523,881 | $-523,881 |
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Insider Activity of Arvinas, Inc.
Over the last 12 months, insiders at Arvinas, Inc. have bought $0 and sold $845,974 worth of Arvinas, Inc. stock.
On average, over the past 5 years, insiders at Arvinas, Inc. have bought $20.71M and sold $28.58M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 285,714 shares for transaction amount of $20M was made by Ratcliffe Liam (director) on 2020‑12‑18.
List of Insider Buy and Sell Transactions, Arvinas, Inc.
| 2025-03-18 | Sale | Berkowitz Noah | Chief Medical Officer | 8,658 0.0128% | $8.59 | $74,372 | -11.88% | |
| 2025-02-24 | Sale | Houston John G | President and CEO | 31,338 0.0429% | $16.72 | $523,881 | -50.09% | |
| 2025-02-24 | Sale | Taylor Ian | President, R&D | 9,020 0.0123% | $16.71 | $150,752 | -50.09% | |
| 2025-02-24 | Sale | Cacace Angela M | Chief Scientific Officer | 4,207 0.0057% | $16.70 | $70,238 | -50.09% | |
| 2025-02-24 | Sale | Loomis David K | Chief Accounting Officer | 1,214 0.0017% | $16.75 | $20,335 | -50.09% | |
| 2024-11-07 | Sale | Loomis David K | Chief Accounting Officer | 231 0.0003% | $27.69 | $6,396 | -35.96% | |
| 2024-02-23 | Sale | Houston John G | President and CEO | 5,196 0.0095% | $47.05 | $244,472 | -44.89% | |
| 2024-02-23 | Sale | Cassidy Sean A | Chief Financial Officer | 1,702 0.0031% | $47.05 | $80,079 | -44.89% | |
| 2024-02-23 | Sale | Taylor Ian | Chief Scientific Officer | 1,701 0.0031% | $47.05 | $80,032 | -44.89% | |
| 2024-02-23 | Sale | Peck Ronald | Chief Medical Officer | 1,699 0.0031% | $47.05 | $79,938 | -44.89% | |
| 2023-11-08 | Sale | Loomis David K | Chief Accounting Officer | 229 0.0004% | $17.05 | $3,904 | +80.56% | |
| 2023-08-11 | Sale | Peck Ronald | Chief Medical Officer | 1,324 0.0024% | $24.39 | $32,289 | +20.32% | |
| 2023-03-01 | Sale | Houston John G | President and CEO | 5,878 0.0107% | $29.53 | $173,577 | -14.30% | |
| 2023-03-01 | Sale | Cassidy Sean A | Chief Financial Officer | 1,745 0.0032% | $29.53 | $51,530 | -14.30% | |
| 2023-03-01 | Sale | Taylor Ian | Chief Scientific Officer | 1,051 0.0019% | $29.53 | $31,036 | -14.30% | |
| 2022-08-12 | Sale | Peck Ronald | Chief Medical Officer | 1,258 0.0024% | $54.84 | $68,994 | -40.82% | |
| 2022-04-14 | Sale | Morrison Briggs | 10,754 0.0202% | $67.03 | $720,888 | -36.79% | ||
| 2022-03-11 | Sale | Cassidy Sean A | Chief Financial Officer | 15,000 0.029% | $70.00 | $1.05M | -36.08% | |
| 2022-03-04 | Sale | Houston John G | President and CEO | 6,024 0.0113% | $63.94 | $385,175 | -31.76% | |
| 2022-03-04 | Sale | Cassidy Sean A | Chief Financial Officer | 1,593 0.003% | $63.94 | $101,856 | -31.76% |
Total: 100
*Gray background shows transactions not older than one year
Insider Historical Profitability
31.29%
| Houston John G | President and CEO | 1157480 1.5858% | $7.03M | 1 | 11 | +24.92% |
| Taylor Ian | President, R&D | 159121 0.218% | $965,864.47 | 1 | 13 | +66.46% |
| Berkowitz Noah | Chief Medical Officer | 110023 0.1507% | $667,839.61 | 0 | 1 | |
| Cacace Angela M | Chief Scientific Officer | 97231 0.1332% | $590,192.17 | 0 | 1 | |
| Loomis David K | Chief Accounting Officer | 18863 0.0258% | $114,498.41 | 0 | 3 | |
| RA CAPITAL MANAGEMENT, LLC | 3138412 4.2997% | $19.05M | 1 | 0 | +24.92% | |
| SHANNON TIMOTHY M | director | 1653128 2.2648% | $10.03M | 5 | 11 | +45.5% |
| Flynn James E | 10 percent owner | 411245 0.5634% | $2.5M | 1 | 0 | +24.92% |
| Loven Jakob | director | 312500 0.4281% | $1.9M | 1 | 0 | +24.92% |
| Ratcliffe Liam | director | 185686 0.2544% | $1.13M | 3 | 10 | +24.96% |
| Cassidy Sean A | Chief Financial Officer | 181916 0.2492% | $1.1M | 1 | 13 | +24.92% |
| 5AM VENTURES III, L.P. | 10 percent owner | 91162 0.1249% | $553,353.34 | 0 | 4 | |
| Peck Ronald | Chief Medical Officer | 67516 0.0925% | $409,822.12 | 0 | 8 | |
| Kennedy Edward Moore Jr. | director | 42718 0.0585% | $259,298.26 | 2 | 0 | +24.92% |
| Morrison Briggs | 19976 0.0274% | $121,254.32 | 1 | 2 | ||
| Margus Bradley Albert | director | 2000 0.0027% | $12,140.00 | 1 | 5 | +24.92% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$14,527,743 | 76 | 38.40% | $516.52M | |
$24,384,691 | 42 | -30.27% | $438.98M | |
$6,280,187 | 19 | 6.80% | $399.52M | |
$3,287,638 | 15 | -0.23% | $459.12M | |
$18,945,106 | 14 | -27.94% | $485.98M | |
$18,455,830 | 13 | 24.59% | $420.51M | |
Arvinas, Inc. (ARVN) | $133,809,976 | 13 | 31.29% | $443.06M |
$3,073,199 | 10 | 16.77% | $410.94M | |
$11,541,901 | 10 | 8.07% | $496.07M | |
$94,976,497 | 10 | -10.72% | $490.83M | |
$1,580,951 | 9 | -14.18% | $455.08M | |
$38,624,786 | 9 | 1.26% | $420.77M | |
$73,280,625 | 6 | -41.09% | $513.38M | |
$18,704,399 | 5 | -20.93% | $401.49M | |
$3,200,000 | 5 | -11.36% | $474.9M | |
$960,000 | 2 | 15.91% | $458.3M | |
$3,250,000 | 1 | -44.91% | $398.17M | |
$504,640 | 1 | 16.84% | $432.59M | |
$3,850,000 | 1 | -51.32% | $417.84M |
ARVN Institutional Investors: Active Positions
| Increased Positions | 111 | +52.86% | 14M | +19.26% |
| Decreased Positions | 88 | -41.9% | 10M | -14.26% |
| New Positions | 29 | New | 4M | New |
| Sold Out Positions | 32 | Sold Out | 6M | Sold Out |
| Total Postitions | 233 | +10.95% | 76M | +5% |
ARVN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $54,523.00 | 9.68% | 7.06M | +56,561 | +0.81% | 2024-12-31 |
| Ecor1 Capital, Llc | $51,929.00 | 9.21% | 6.73M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $47,629.00 | 8.45% | 6.17M | -396,543 | -6.04% | 2025-03-31 |
| Price T Rowe Associates Inc /Md/ | $31,675.00 | 5.62% | 4.1M | +249,295 | +6.47% | 2024-12-31 |
| Rtw Investments, Lp | $25,741.00 | 4.57% | 3.33M | +551,979 | +19.84% | 2024-12-31 |
| Citadel Advisors Llc | $23,721.00 | 4.21% | 3.07M | +365,117 | +13.48% | 2024-12-31 |
| Bellevue Group Ag | $18,448.00 | 3.27% | 2.39M | +3,000 | +0.13% | 2024-12-31 |
| T. Rowe Price Investment Management, Inc. | $17,048.00 | 3.03% | 2.21M | +2M | New | 2024-12-31 |
| Ubs Group Ag | $15,737.00 | 2.79% | 2.04M | +2M | +332.26% | 2024-12-31 |
| Jpmorgan Chase & Co | $14,337.00 | 2.54% | 1.86M | -472,225 | -20.27% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.